The “Alzheimer’s Disease (AD)– Pipeline Insights, 2018″ report covers in-depth analysis on Alzheimer’s disease drug molecules currently undergoing clinical studies. It provides a deep understanding of potential Alzheimer’s disease drug molecules across all drug development phases.
The report assesses the pipeline Alzheimer’s disease molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products), molecule type (Small molecules, Biologics and others), drug target (Tau protein, VLDLR and ApoER2, CYP46A1, and others), mechanism of action (gene therapy and cell replacements), and route of administration (Intracerebral, IV, and others).
The report provides a snapshot of discontinued and dormant drugs too. In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
The report covers company profiles key players in developing Alzheimer’s disease drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.
The scope of the report
Provides comprehensive understanding about active Alzheimer’s disease pipeline drug candidates
Includes all-inclusive pipeline product coverage with segregation by various stages of pipeline from discovery to late-stage.
Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
Provides a comparative analysis of key marketed products and pipeline drug candidates
Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
Provides key info on players involved in clinical R&D of Alzheimer’s disease drug candidates.
Provides in-depth coverage of key news related to Alzheimer’s disease drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.
Reasons To Buy
To obtain an understanding of the current Alzheimer’s disease pipeline landscape.
To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
To valuably optimize R&D activities in-line with robust therapeutic drug markets.
To devise strategic initiatives by identifying prospective partners with progressing projects.
